Skip to main content
logo
Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
24.52
-0.08 (-0.33%)
At close: Mar 24, 2026, 4:00 PM EDT
24.49
-0.03 (-0.13%)
After-hours: Mar 24, 2026, 5:46 PM EDT

Oculis Holding AG Revenue

In the year 2025, Oculis Holding AG had annual revenue of 1.20M CHF with 74.78% growth. Oculis Holding AG had revenue of 411.00K in the quarter ending December 31, 2025, with 13,600.00% growth.

Revenue (ttm)
1.20M CHF
Revenue Growth
+74.78%
P/S Ratio
959.50
Revenue / Employee
24,469 CHF
Employees
49
Market Cap
1.45B USD

Revenue Chart

* This company reports financials in CHF.

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20251.20M513.00K74.78%
Dec 31, 2024686.00K-197.00K-22.31%
Dec 31, 2023883.00K-29.00K-3.18%
Dec 31, 2022912.00K-48.00K-5.00%
Dec 31, 2021960.00K-33.00K-3.32%
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Novavax1.12B
Immunocore Holdings400.02M
Iovance Biotherapeutics263.50M
Nurix Therapeutics83.98M
Intellia Therapeutics67.67M
Nuvation Bio62.90M
Generate Biomedicines31.89M
Nanobiotix11.93M
Revenue Rankings

OCS News

More News